Skip to main content
. 2022 May 23;13:2853. doi: 10.1038/s41467-022-30304-9

Fig. 4. Dye@DIII exhibited improved pharmacokinetics compared with free dye and could be modified with targeting molecules.

Fig. 4

a NIR-II images of mice injected with free IR-783 or IR-783@DIII. Li: liver; Ki: kidney; In: intestine. b SBR of free IR-783 and IR-783@DIII in the liver and kidneys (n = 3). c NIR-II images of mice injected with IR-780@DIII or ICG@DIII. d Left: Schematic representation of the process for editing the DIII coating with the biofunctional molecules TATE and PSMA-617. Right: NIR-II images of free IR-783, IR-783@DIII, IR-783@DIII-molecular conjugate, and DIII. e, f UHPLC-MS analysis was used to confirm the successful modification of DIII with PSMA-617 (labeled as PSMA) or TATE. 3–5 molecules could be successfully conjugated to one DIII. g, h NIR-II microscopy images of IR-783@DIII-TATE uptake by SSTR-overexpressing AR42J cells (g) and IR-783@DIII-PSMA-617 uptake by PSMA-overexpressing PC3-PIP cells (h). i–j NIR-II images of an AR42J tumor-bearing mouse injected with IR-783@DIII-TATE (i) and the biodistributions of targeted and untargeted complexes at 12 h p.i. j (n = 3). a.u., arbitrary units. k NIR-II microscopy images of PC3 and PC3-PIP tumor-bearing mice injected with IR-783@DIII-PSMA-617. Data are presented as mean ± s.d. of three independent experiments. Source data are provided as a Source Data file.